William Blair analyst Brandon Vazquez has maintained their bullish stance on PODD stock, giving a Buy rating on October 30.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Vazquez has given his Buy rating due to a combination of factors including Insulet’s strong third-quarter performance, which exceeded market expectations in both sales and earnings per share. The company showed robust growth in both U.S. and international markets, particularly with its Omnipod revenues. This growth was driven by increased adoption among patients transitioning from multiple daily injections and those with type 2 diabetes.
Additionally, Insulet’s international expansion has been bolstered by successful product launches in new countries and favorable reimbursement agreements, particularly in Norway. The positive quarterly results also reflect well on the new CEO, Ashley McEvoy, as she takes the helm. With the stock trading at a reasonable multiple of future sales estimates, Vazquez maintains a positive outlook on the company’s potential for continued growth.
In another report released on October 30, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $349.00 price target.